Crinetics Pharmaceuticals Statistics
Total Valuation
CRNX has a market cap or net worth of $2.91 billion. The enterprise value is $1.76 billion.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRNX has 94.18 million shares outstanding. The number of shares has increased by 30.19% in one year.
| Current Share Class | 94.18M |
| Shares Outstanding | 94.18M |
| Shares Change (YoY) | +30.19% |
| Shares Change (QoQ) | +0.74% |
| Owned by Insiders (%) | 1.48% |
| Owned by Institutions (%) | 113.49% |
| Float | 92.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,090.54 |
| Forward PS | 143.45 |
| PB Ratio | 2.36 |
| P/TBV Ratio | 2.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,266.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.80, with a Debt / Equity ratio of 0.04.
| Current Ratio | 17.80 |
| Quick Ratio | 17.49 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.94% and return on invested capital (ROIC) is -25.12%.
| Return on Equity (ROE) | -36.94% |
| Return on Assets (ROA) | -23.77% |
| Return on Invested Capital (ROIC) | -25.12% |
| Return on Capital Employed (ROCE) | -34.64% |
| Revenue Per Employee | $3,185 |
| Profits Per Employee | -$846,302 |
| Employee Count | 437 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.70% in the last 52 weeks. The beta is 0.33, so CRNX's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -42.70% |
| 50-Day Moving Average | 30.09 |
| 200-Day Moving Average | 37.70 |
| Relative Strength Index (RSI) | 56.52 |
| Average Volume (20 Days) | 1,001,514 |
Short Selling Information
The latest short interest is 13.17 million, so 13.99% of the outstanding shares have been sold short.
| Short Interest | 13.17M |
| Short Previous Month | 12.24M |
| Short % of Shares Out | 13.99% |
| Short % of Float | 14.20% |
| Short Ratio (days to cover) | 16.39 |
Income Statement
In the last 12 months, CRNX had revenue of $1.39 million and -$369.83 million in losses. Loss per share was -$4.12.
| Revenue | 1.39M |
| Gross Profit | -244.63M |
| Operating Income | -423.06M |
| Pretax Income | -258.54M |
| Net Income | -369.83M |
| EBITDA | -419.62M |
| EBIT | -423.06M |
| Loss Per Share | -$4.12 |
Full Income StatementBalance Sheet
The company has $1.20 billion in cash and $49.94 million in debt, giving a net cash position of $1.15 billion or $12.17 per share.
| Cash & Cash Equivalents | 1.20B |
| Total Debt | 49.94M |
| Net Cash | 1.15B |
| Net Cash Per Share | $12.17 |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 12.45 |
| Working Capital | 1.15B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$299.77 million and capital expenditures -$6.00 million, giving a free cash flow of -$305.77 million.
| Operating Cash Flow | -299.77M |
| Capital Expenditures | -6.00M |
| Free Cash Flow | -305.77M |
| FCF Per Share | -$3.25 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -30,392.17% |
| Pretax Margin | -26,568.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.19% |
| Shareholder Yield | -30.19% |
| Earnings Yield | -12.71% |
| FCF Yield | -10.51% |
Analyst Forecast
The average price target for CRNX is $74.33, which is 140.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $74.33 |
| Price Target Difference | 140.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 309.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRNX has an Altman Z-Score of 18.53 and a Piotroski F-Score of 2.
| Altman Z-Score | 18.53 |
| Piotroski F-Score | 2 |
